Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndromes

被引：11

作者：

Tamburini, J. ^{[1
]}

Elie, C. ^{[2
]}

Park, S. ^{[1
]}

Beyne-Rauzy, O. ^{[3
]}

Gardembas, M. ^{[4
]}

Berthou, C. ^{[5
]}

Mahe, B. ^{[6
]}

Sanhes, L. ^{[7
]}

Stamatoullas, A. ^{[8
]}

Vey, N. ^{[9
]}

Aouba, A.

Slama, B. ^{[10
]}

Quesnel, B. ^{[11
]}

Vekhoff, A. ^{[13
]}

Sotto, J. J. ^{[12
]}

Vassilief, D. ^{[1
]}

Al-Nawakil, C. ^{[1
]}

Fenaux, P. ^{[14
]}

Dreyfus, F. ^{[1
]}

Bouscary, D. ^{[1
]}

机构：

[1] Hop Cochin, Dept Haematol, Paris, France

[2] Univ Paris 05, Dept Biostat, F-75270 Paris 06, France

[3] Hop Purpan, Dept Hematol Odile, Toulouse, France

[4] Ctr Hosp Angers, Dept Hematol Martine, Angers, France

[5] Hop Brest, Dept Hematol Christian, Brest, France

[6] Ctr Hosp Nantes, Dept Hematol, Nantes, France

[7] Ctr Hosp Perpignan, Dept Hematol, Perpignan, France

[8] Ctr Hosp Rouen, Dept Hematol Aspasia, Rouen, France

[9] Inst J Paoli I Calmettes, Dept Hematol, F-13009 Marseille, France

[10] Ctr Hosp Avignon, Dept Hematol, Avignon, France

[11] Ctr Hosp Lille, Dept Hematol, Lille, France

[12] Ctr Hosp Grenoble, Dept Hematol, Grenoble, France

[13] Hop Hotel Dieu, Dept Hematol, F-75181 Paris, France

[14] Hop Avicenne, Dept Hematol, Bobigny, France

来源：

LEUKEMIA RESEARCH | 2009年 / 33卷 / 04期

关键词：

INTERNATIONAL WORKING GROUP; RESPONSE CRITERIA; ANEMIA; PROPOSAL;

D O I：

10.1016/j.leukres.2008.06.005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：547 / 550

页数：4

共 50 条

[41] Twice-Weekly High-Dose rHuEpo for the Treatment of Anemia in Patients with Low-Risk Myelodysplastic Syndromes
Latagliata, R.
Oliva, E. N.
Volpicelli, P.
Carmosino, I.
Breccia, M.
Vincelli, I.
Alati, C.
Napoleone, L.
Vozella, F.
Nobile, F.
Alimena, G.
ACTA HAEMATOLOGICA, 2008, 120 (02) : 104 - 107
[42] Luspatercept as first line in transfusiondependant very low to intermediate risk myelodysplastic syndromes
Tauveron-Jalenques, Urbain
Requena, Gaspar Aspas
BULLETIN DU CANCER, 2025, 112 (02) : 113 - 114
[43] Low-risk delivery characteristics associated with very low sepsis risk
Banerjee, Sujoy
JOURNAL OF PEDIATRICS, 2022, 247 : 179 - 180
[44] Very low-risk versus low-risk prostate cancer: A distinction worth keeping
Epstein, Jonathan I.
PROSTATE, 2021, 81 (13): : 923 - 925
[45] DNA instability in low-risk myelodysplastic syndromes: refractory anemia with or without ring sideroblasts
Novotna, Bozena
Neuwirtova, Radana
Siskova, Magda
Bagryantseva, Yana
HUMAN MOLECULAR GENETICS, 2008, 17 (14) : 2144 - 2149
[46] ROLE OF ERYTHROPOIESIS STIMULATING AGENTS (ESAS) IN SUPPORTIVE CARE OF LOW-RISK MYELODYSPLASTIC SYNDROMES
Cerchione, C.
Martinelli, G.
Soriente, I.
D'Arco, A. M.
Danise, P.
Cerciello, G.
Di Battista, V.
Cangini, D.
Giannini, M. B.
Pane, F.
Alfinito, F.
HAEMATOLOGICA, 2019, 104 : 147 - 148
[47] DNA instability in low-risk myelodysplastic syndromes - refractory anemia with or without ring sideroblasts
Novotna, B.
Blazkova, V.
Neuwirtova, R.
Siskova, M.
Bagryantseva, Y.
LEUKEMIA RESEARCH, 2007, 31 : S72 - S72
[48] Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements
Angel F. Remacha
Beatriz Arrizabalaga
Consuelo Del Cañizo
Guillermo Sanz
Ana Villegas
Annals of Hematology, 2010, 89 : 147 - 154
[49] Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements
Remacha, Angel F.
Arrizabalaga, Beatriz
Del Canizo, Consuelo
Sanz, Guillermo
Villegas, Ana
ANNALS OF HEMATOLOGY, 2010, 89 (02) : 147 - 154
[50] Impact of Erythropoietic Stimulating Agents on Mutational Composition in Patients with Low-Risk Myelodysplastic Syndromes
Patel, Bhumika
Saygin, Caner
Przychodzen, Bartlomiej P.
Kuzmanovic, Teodora
Hirsch, Cassandra M.
Clemente, Michael J.
Thota, Swapna
Nazha, Aziz
Mikkael, Sekeres A.
Maciejewski, Jaroslaw P.
Carraway, Hetty E.
BLOOD, 2016, 128 (22)

← 1 2 3 4 5 →